Quick Answer
Travere Therapeutics, Inc. reported Stockholders Equity of $114.83 million for fiscal year 2025.
Travere Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $114.83M | +94.4% |
| 2024 | $59.08M | -70.6% |
| 2023 | $200.81M | +368.6% |
| 2022 | $42.85M | -85.8% |
| 2021 | $302.11M | +43.0% |
| 2020 | $211.21M | -4.5% |
| 2019 | $221.20M | -30.5% |
| 2018 | $318.25M | +8.6% |
| 2017 | $293.13M | -4.8% |
| 2016 | $307.77M | +2.6% |
| 2015 | $299.97M | +905.3% |
| 2014 | -$37.25M | -89.4% |
| 2013 | -$19.67M | -477.1% |
| 2012 | -$3.41M | -5302.7% |
| 2012 | -$63.1K | +88.2% |
| 2011 | -$536.3K | -790.0% |
| 2011 | -$60.3K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $73.56M | +341.6% | +124.6% |
| June 30, 2025 | $32.75M | +116.2% | -0.2% |
| March 31, 2025 | $32.82M | -55.7% | -44.4% |
| December 31, 2024 | $59.08M | -70.6% | +294.0% |
| September 30, 2024 | -$30.45M | -110.9% | -301.1% |
| June 30, 2024 | $15.15M | -87.0% | -79.6% |
| March 31, 2024 | $74.07M | -60.8% | -63.1% |
| December 31, 2023 | $200.81M | +368.6% | -28.2% |
- Travere Therapeutics, Inc. showed an increase of +94.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2011–2025 period, Travere Therapeutics, Inc.’s stockholders equity has grown by 190670.1% (from -$60.3 thousand to $114.83 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: